These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma. Seibel I; Cordini D; Hager A; Tillner J; Riechardt AI; Heufelder J; Davids AM; Rehak M; Joussen AM Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1787-92. PubMed ID: 27376824 [TBL] [Abstract][Full Text] [Related]
4. Salvage proton beam therapy in local recurrent uveal melanoma. Riechardt AI; Cordini D; Dobner B; Seibel I; Gundlach E; Rehak M; Hager A; Stark R; Moser L; Joussen AM Am J Ophthalmol; 2014 Nov; 158(5):948-56. PubMed ID: 25038327 [TBL] [Abstract][Full Text] [Related]
5. Long-term Outcomes After Proton Beam Irradiation in Patients With Large Choroidal Melanomas. Papakostas TD; Lane AM; Morrison M; Gragoudas ES; Kim IK JAMA Ophthalmol; 2017 Nov; 135(11):1191-1196. PubMed ID: 29049518 [TBL] [Abstract][Full Text] [Related]
6. Local Recurrence After Primary Proton Beam Therapy in Uveal Melanoma: Risk Factors, Retreatment Approaches, and Outcome. Seibel I; Cordini D; Rehak M; Hager A; Riechardt AI; Böker A; Heufelder J; Weber A; Gollrad J; Besserer A; Joussen AM Am J Ophthalmol; 2015 Oct; 160(4):628-36. PubMed ID: 26133249 [TBL] [Abstract][Full Text] [Related]
12. Trabeculectomy in patients with uveal melanoma after proton beam therapy. Riechardt AI; Cordini D; Rehak M; Hager A; Seibel I; Böker A; Gundlach E; Heufelder J; Joussen AM Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1379-85. PubMed ID: 26960442 [TBL] [Abstract][Full Text] [Related]
13. Long-term Risk of Melanoma-Related Mortality for Patients With Uveal Melanoma Treated With Proton Beam Therapy. Lane AM; Kim IK; Gragoudas ES JAMA Ophthalmol; 2015 Jul; 133(7):792-6. PubMed ID: 25905597 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of uveal melanoma with iodine 125 plaques or proton beam therapy: indications and comparison of local recurrence rates]. Desjardins L; Lumbroso L; Levy C; Mazal A; Delacroix S; Rosenwald JC; Dendale R; Plancher C; Asselain B J Fr Ophtalmol; 2003 Mar; 26(3):269-76. PubMed ID: 12746603 [TBL] [Abstract][Full Text] [Related]
15. Repeat Episcleral Plaque Brachytherapy: Clinical Outcomes in Patients Treated for Locally Recurrent Posterior Uveal Melanoma. King B; Morales-Tirado VM; Wynn HG; Gao BT; Ballo MT; Wilson MW Am J Ophthalmol; 2017 Apr; 176():40-45. PubMed ID: 28048976 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant proton beam irradiation followed by transscleral resection of uveal melanoma in 106 cases. Willerding GD; Cordini D; Moser L; Krause L; Foerster MH; Bechrakis NE Br J Ophthalmol; 2016 Apr; 100(4):463-7. PubMed ID: 26224096 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy. Mahdjoubi A; Najean M; Lemaitre S; Dureau S; Dendale R; Levy C; Rouic LL; Desjardins L; Cassoux N Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):411-420. PubMed ID: 29116399 [TBL] [Abstract][Full Text] [Related]
18. Results of proton radiotherapy for uveal melanomas. Egger E; Zografos L; Munkel G; Böhringer T; Bercher L; Chamot L Front Radiat Ther Oncol; 1997; 30():111-22. PubMed ID: 9205891 [No Abstract] [Full Text] [Related]
19. Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters. Mishra KK; Daftari IK; Weinberg V; Cole T; Quivey JM; Castro JR; Phillips TL; Char DH Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):330-6. PubMed ID: 23886415 [TBL] [Abstract][Full Text] [Related]
20. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy. Conway RM; Poothullil AM; Daftari IK; Weinberg V; Chung JE; O'Brien JM Arch Ophthalmol; 2006 Jun; 124(6):838-43. PubMed ID: 16769837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]